EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	6626	((544/122,319,328,333) or (514/235.8,256)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/03/30 10:36

C:\Program Files\Stnexp\Queries\10505146 (b).str





chain nodes :
7 15 18 23
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14 26 27 28 29 30
ring/chain nodes :
21 22 24
chain bonds :
2-7 5-9 15-21 15-22 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 26-27 26-30 27-28 28-29 29-30
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 4-5 5-6 15-21 15-22 23-24 26-27 26-30 27-28 28-29 29-30
exact bonds :
5-9
normalized bonds :
9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 : 26 :

G1:O,Cl,Br,F,I,NH2,[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS
18:CLASS 19:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
Generic attributes :
7:

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :
Node 7: Limited
C,C5
N,N1
O,O0
S,S0

C:\Program Files\Stnexp\Queries\10505146 (sub).str





chain nodes :
7 9 10
ring nodes :
1 2 3 4 5 6
chain bonds :
7-9 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact bonds :
7-9 9-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:CLASS

=>
Uploading C:\Program Files\Stnexp\Queries\10505146.str





chain nodes :
7 19
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
ring/chain nodes :
16
chain bonds :
2-7
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 4-5 5-6
normalized bonds :
9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

G1:O,Cl,Br,F,I,[*1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 19:CLASS 20:Atom
Generic attributes :
7:

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :
Node 7: Limited
C,C5
N,N1
O,O0
S,S0

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,Cl,Br,F,I,[@1]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 23:52:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 92725 TO ITERATE

2.2% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 1836418 TO 1872582
PROJECTED ANSWERS: 519 TO 1335

L2 1 SEA SSS SAM L1

=> =>
Uploading C:\Program Files\Stnexp\Queries\10505146 (a).str



chain nodes :
7 18
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
ring/chain nodes :
15
chain bonds :
2-7 5-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 4-5 5-6
exact bonds :
5-9
normalized bonds :
9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

G1:O,Cl,Br,F,I,[*1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:CLASS 18:CLASS 19:Atom
Generic attributes :
7:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :
Node 7: Limited
C,C5
N,N1
O,O0
S,S0

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 O,Cl,Br,F,I,[@1]

Structure attributes must be viewed using STN Express query preparation.

```
=> s l3 sss sam
SAMPLE SEARCH INITIATED 23:53:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     7099 TO ITERATE

 28.2% PROCESSED     2000 ITERATIONS                                 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       136929 TO   147031
PROJECTED ANSWERS:              57 TO      509

L4            4 SEA SSS SAM L3

=> =>
Uploading C:\Program Files\Stnexp\Queries\10505146 (b).str
```





```
chain nodes :
7  15  18  23
ring nodes :
1  2  3  4  5  6  9  10  11  12  13  14  26  27  28  29  30
ring/chain nodes :
21  22  24
chain bonds :
2-7  5-9  15-21  15-22  23-24
```

```
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  9-10  9-14  10-11  11-12  12-13  13-14  26-27  26-30
27-28  28-29  29-30
exact/norm bonds :
1-2  1-6  2-3  2-7  3-4  4-5  5-6  15-21  15-22  23-24  26-27  26-30  27-28  28-29
29-30
exact bonds :
5-9
normalized bonds :
9-10  9-14  10-11  11-12  12-13  13-14
isolated ring systems :
containing 1 : 9 : 26 :


G1:O,Cl,Br,F,I,NH2,[*1],[*2],[*3]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  9:Atom  10:Atom  11:Atom
12:Atom  13:Atom  14:Atom  15:CLASS  18:CLASS  19:Atom  21:CLASS  22:CLASS
23:CLASS  24:CLASS  26:Atom  27:Atom  28:Atom  29:Atom  30:Atom
Generic attributes :
7:
Saturation             : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System    : Monocyclic

Element Count :
Node 7: Limited
    C,C5
    N,N1
    O,O0
    S,S0



L5      STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l5 sss sam
SAMPLE SEARCH INITIATED 23:58:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     7073 TO ITERATE

 28.3% PROCESSED     2000 ITERATIONS                                  5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
```

```
PROJECTED ITERATIONS:        136418 TO   146502
PROJECTED ANSWERS:              101 TO      605

L6            5 SEA SSS SAM L5

=> => s l5 sss ful
FULL SEARCH INITIATED 00:02:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   143707 TO ITERATE

100.0% PROCESSED   143707 ITERATIONS  (     1 INCOMPLETE)      252 ANSWERS
SEARCH TIME: 00.00.02

L7          252 SEA SSS FUL L5

=>
Uploading C:\Program Files\Stnexp\Queries\10505146 (sub).str
```





```
chain nodes :
7  9  10
ring nodes :
1  2  3  4  5  6
chain bonds :
7-9  9-10
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact bonds :
7-9  9-10


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS




L8      STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l8 sss sam sub=l7
SAMPLE SUBSET SEARCH INITIATED 00:05:21 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -        3 TO ITERATE

100.0% PROCESSED         3 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):            3 TO      163
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):               3 TO      163

L9             3 SEA SUB=L7 SSS SAM L8

=> => s l8 sss ful sub=l7
FULL SUBSET SEARCH INITIATED 00:05:51 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -       38 TO ITERATE

100.0% PROCESSED        38 ITERATIONS                              35 ANSWERS
SEARCH TIME: 00.00.01

L10           35 SEA SUB=L7 SSS FUL L8

=> s l7 not l10
L11         217 L7 NOT L10

=> => s l11
L12          31 L11

=> d l12 1-31 bib,ab,hitstr
```

L12 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:257497 CAPLUS
TI Protein phosphorylation sites in leukemia-related signaling pathway proteins and reagents for their detection
IN Polakiewicz, Roberto; Goss, Valerie; Lee, Kimberly; Gu, Ting-Lei; Moritz, Albrecht
PA Cell Signaling Technology, Inc., USA
SO PCT Int. Appl., 243pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007027957	A2	20070308	WO 2006-US34126	20060830

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-712776P P 20050831

AB The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human leukemia, and provides phosphorylation site-specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin-binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators, and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, Ig superfamily proteins, inhibitor proteins, protein kinases lipid kinases, ligases, lipid-binding proteins, methyltransferases, motor proteins, oxidoreductases, phosphatases, phosphodiesterases, phospholipases, proteases, receptor proteins, transcription factors transferases, translation/transporter proteins, and ubiquitin-conjugating system proteins.

IT INDEXING IN PROGRESS
IT 928124-02-1
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(protein phosphorylation sites in leukemia-related signaling pathway proteins and reagents for their detection)
RN 928124-02-1 CAPLUS
CN L-Arginine, L-alanylglycyl-L-α-aspartyl-L-asparaginyl-L-seryl-L-glutaminyl-L-seryl-L-valyl-L-tyrosyl-L-isoleucyl-L-prolyl-L-methionyl-L-seryl-L-prolylglycyl-L-alanyl-L-histidyl-L-histidyl-L-phenylalanyl-L-α-aspartyl-L-seryl-L-leucylglycyl-L-tyrosyl-L-prolyl-L-seryl-L-threonyl-L-threonyl-L-leucyl-L-prolyl-L-valyl-L-histidyl- (CA INDEX NAME)

L12 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1189306 CAPLUS
DN 146:121916
TI An efficient one-pot construction of substituted pyrimidinones
AU Lu, Yuelie; Xiang, Tingjian; Bartberger, Michael D.; Bernard, Charles; Bostick, Tracy; Huang, Liang; Liu, Longbin; Siegmund, Aaron; Sukay, Gregory; Guo, Gary; Elipe, Maria Silva; Tormos, Wanda; Dominguez, Celia; Koch, Kevin; Burgess, Laurence E.; Basil, Thomas C.; Ibrahim, Prabha; Hummel, Conrad
CS Chemical Process Research and Development, Amgen Inc., Thousand Oaks, CA, 91320-1799, USA
SO Tetrahedron (2006), 62(50), 11714-11723
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 146:121916
AB A concise, scalable synthesis of 5-aryl-3-methyl-2-methylthio-6-pyridin-4-yl-3H-pyrimidin-4-ones (aryl = 3-MeC6H4, 4-FC6H4, 3,4-Cl2C6H3, 2-naphthyl, etc.), as building block for p38 kinase inhibitor B, from Et arylacetates, 4-cyanopyridine and Me isothiocyanate is described. Subsequent hydrolysis of the methylthio group to the hydroxy group and chlorination provided the key intermediates, 2-chloro-3-methyl-6-pyridin-4-yl-5-aryl-3H-pyrimidin-4-ones. This class of reactive building blocks enabled the rapid evaluation of a variety of side chains at the 2-position of the pyrimidinone in SAR studies of inhibitors of p38 MAP kinase.
IT 918304-17-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(one-pot preparation of aryl(methylthio)(pyridyl)pyrimidinones and derivs. via heterocyclization of arylacetates with cyanopyridines and Me isothiocyanate)
RN 918304-17-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(3-methylphenyl)-2,6-di-4-pyridinyl- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:768723 CAPLUS
DN 145:180954
TI Substituted 5-phenylpyrimidines for use in cancer therapy
IN Rheinheimer, Joachim; Grote, Thomas; Mueller, Bernd; Nave, Barbara; Schieweck, Frank; Schwoegler, Anja; Jabs, Thorsten; Blettner, Carsten
PA BASF Aktiengesellschaft, Germany
SO PCT Int. Appl., 60pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006079556	A2	20060803	WO 2006-EP774	20060130
WO 2006079556	A3	20060921		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2005-1955 A 20050131
OS MARPAT 145:180954
AB The invention discloses substituted 5-phenylpyrimidines I [X = NR1R2, OR1a, SR1a, (R1, R2 = H, C1-C10 alkyl, C2-C6-alkenyl, etc.; R1a = R1 except for hydrogen); Y = halo, cyano, C1-C4-alkyl, etc.; R4 = radical of 1-15 atoms different from H; L = radical of 1-10 atoms different from H; n = 0-5], or a pharmaceutically acceptable salt thereof, for use in therapy, in particular for the therapy of cancerous diseases.
IT 585535-49-5 585535-62-2 585535-67-7
585535-68-8 585535-82-6 585536-07-8
585536-08-9 585536-11-4 585536-15-8
585536-16-9 585536-18-1 585536-30-7
585536-34-1 585536-36-3 585536-38-5
903547-67-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenylpyrimidine derivs. for cancer therapy)
RN 585535-49-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(1-methylethyl)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-62-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(2-pyridinyl)-N-[(1S)-2,2,2-trifluoro-1-

methylethyl]-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-67-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(1-methylethyl)-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-68-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(6-methyl-2-pyridinyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-82-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(4-methyl-2-pyridinyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-07-8 CAPLUS
CN Pyrimidine, 4-chloro-5-(2,6-difluoro-4-methoxyphenyl)-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-08-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N-(1-methylethyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-11-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N-(1-methylpropyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-15-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-cyclopentyl-5-(2,6-difluoro-4-methoxyphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-16-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N-[(1S)-1,2-dimethylpropyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-18-1 CAPLUS
CN Phenol, 4-[4-chloro-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 585536-30-7 CAPLUS
CN Pyrimidine, 4-chloro-5-(2,6-difluorophenyl)-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-34-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluorophenyl)-N-[(1S)-1,2-dimethylpropyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-36-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluorophenyl)-N-(1-methylethyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-38-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluorophenyl)-N-[(1R)-1,2-dimethylpropyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 903547-67-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(1-methylethyl)-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:535112 CAPLUS
DN 145:167205
TI Synthesis of trisubstituted pyrimidines by regioselective SNAr and Suzuki reactions of polyhalopyrimidines
AU Large, Jonathan M.; Clarke, Maria; Williamson, David M.; McDonald, Edward; Collins, Ian
CS The Institute of Cancer Research, The Cancer Research UK Centre for Cancer Therapeutics, Belmont, Surrey, SM2 5NG, UK
SO Synlett (2006), (6), 861-864
CODEN: SYNLES; ISSN: 0936-5214
PB Georg Thieme Verlag
DT Journal
LA English
AB An efficient, regioselective approach to the synthesis of trisubstituted pyrimidines was developed. Sequential functionalization of com. available polyhalopyrimidines provided the target compds. in moderate to good overall yields.
IT 901303-69-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of trisubstituted pyrimidines by regioselective SNAr and Suzuki reactions of polyhalopyrimidines)
RN 901303-69-3 CAPLUS
CN Pyrimidine, 5-(4-methoxyphenyl)-4-(1-piperidinyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:54920 CAPLUS
DN 144:128999
TI Preparation of arylpyrimidines as agrochemical fungicides.
IN Rheinheimer, Joachim; Schieweck, Frank; Grote, Thomas; Blettner, Carsten; Schwoegler, Anja; Gewehr, Markus; Grammenos, Wassilios; Huenger, Udo; Mueller, Bernd; Schaefer, Peter; Dietz, Jochen; Speakman, John-Bryan; Scherer, Maria; Strathmann, Siegfried; Schoefl, Ulrich; Stierl, Reinhard
PA BASF Aktiengesellschaft, Germany
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006005571	A1	20060119	WO 2005-EP7517	20050712

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI DE 2004-102004034197 A 20040714
OS MARPAT 144:128999
AB Title compds. [I; Y = O, S; R1 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, alkylamino; R3 = halo, cyano, N3, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkylamino; R4 = 5-6 membered (aromatic) mono- or bicyclic heterocyclyl; B = Ph, 5-6 membered heteroaryl; L = halo, cyano, OCN, NO2, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl], were prepared Thus, pyrazole in DMF was stirred 1 h with NaH in DMF at 0-5° and the resulting solution was added to 4-chloro-6-isopropoxy-2-methylsulfonyl-5-(2,4,6-trifluorophenyl)pyrimidine (preparation given) in DMF over 20 min. followed by stirring overnight to give 4-chloro-6-isopropoxy-2-(pyrazol-1-yl)-5-(2,4,6-trifluorophenyl)pyrimidine. Numerous I at 250 ppm reduced Alternaria solani infection of tomato plants to ≤20%, vs. 90% for untreated controls.
IT 873682-54-3P 873682-57-6P 873682-58-7P
873682-59-8P 873682-60-1P 873682-61-2P
873682-62-3P 873682-63-4P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrimidines as agrochem. fungicides)
RN 873682-54-3 CAPLUS
CN Pyrimidine, 4-chloro-5-(2-chloro-6-fluorophenyl)-6-(1,1-dimethylethoxy)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 873682-57-6 CAPLUS
CN Pyrimidine, 4,6-dibutoxy-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 873682-58-7 CAPLUS
CN Pyrimidine, 4-butoxy-6-chloro-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 873682-59-8 CAPLUS
CN Pyrimidine, 4,6-dipropoxy-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 873682-60-1 CAPLUS
CN Pyrimidine, 4-chloro-6-(1-methylethoxy)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 873682-61-2 CAPLUS
CN Pyrimidine, 4-chloro-6-(1,1-dimethylethoxy)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 873682-62-3 CAPLUS
CN Pyrimidine, 4-chloro-6-propoxy-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 873682-63-4 CAPLUS
CN Pyrimidine, 4-chloro-6-ethoxy-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1154546 CAPLUS
DN 143:422365
TI Preparation of diarylpyridazines and -pyrimidines as inhibitors of serine/threonine kinase (Akt kinase) activity.
PA Merck & Co., Inc., USA; Bilodeau, Mark T.; Chua, Peter C.; Cosford, Nicholas D. P.; Hoffman, Jacob M.; Nagasawa, Johnny Yasuo
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005100344	A1	20051027	WO 2005-US11687	20050405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005233584	A1	20051027	AU 2005-233584	20050405
CA 2561311	A1	20051027	CA 2005-2561311	20050405
EP 1737843	A1	20070103	EP 2005-734336	20050405
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI US 2004-561167P	P	20040409		
WO 2005-US11687	W	20050405		

OS MARPAT 143:422365
AB Title compds. [I; X = N, Y = CH, or X = CH, Y = N; n = 0-4; p = 0-5; R1, R2 = H, (substituted) alkyl, alkoxy, alkylcarbonyl, alkoxycarbonyl, alkynyloxycarbonyl, aryl, aryloxy, arylcarbonyl, aryloxycarbonyl, CO2H, cyano, halo, OH, amino, aminocarbonyl, O, perfluoroalkyl, perfluoroalkoxy, etc.], were prepared Thus, title compound (II) was prepared in 3 steps from 4-phenyl-3,6-dichloropyridazine, dimethylamine, 4-formylphenylboronic acid, and 2-(3-piperidine-4-yl-1H-pyrazol-5-yl)pyridine. Several I inhibited Akt1, Akt2, and/or Akt3 with IC50 ≤50 μM.
IT 868280-59-5P 868280-60-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridazines and pyrimidines as inhibitors of serine/threonine kinase)
RN 868280-59-5 CAPLUS
CN 4(1H)-Pyrimidinone, 5-phenyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 868280-60-8 CAPLUS

CN Pyrimidine, 4-chloro-5-phenyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:371230 CAPLUS
DN 142:430289
TI Preparation of pyrimidine compounds as mixed lymphocyte reaction (MLR) inhibitors
IN Tsuruoka, Hiroyuki; Matsuda, Akihisa; Sugano, Yuichi; Tatsuta, Toru
PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005037801	A1	20050428	WO 2004-JP15955	20041021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005145956	A	20050609	JP 2004-302344	20041018
PRAI JP 2003-360967	A	20031021		

OS MARPAT 142:430289
AB Disclosed is a pyrimidine derivative with excellent MLR inhibitory effect or a pharmacol. acceptable salt thereof. Pyrimidine derivs. represented by the general formula (I) or pharmacol. acceptable salts thereof [R1 = lower alkyl; R2 = each (un)substituted aryl or heterocyclyl; A = NH, O; R3 = H, lower alkyl, heterocyclyl, aryl, heterocyclyl, -NHR6 (wherein R6 = lower alkyl, cycloalkyl-lower alkyl, aralkyl, each (un)substituted cycloalkyl, aryl, or heterocyclyl); R4 = H, lower alkyl, lower alkoxy, cycloalkyl-lower alkyl, aralkyl, each (un)substituted aryl or heterocyclyl; provided that R3 = R4 ≠ H; R5 = H, halo, lower alkyl, cycloalkyl, (un)substituted heterocyclyl, NR7R8, OR7 (wherein R7, R8 = H, cycloalkyl, (un)substituted aryl or lower alkyl)] are prepared These compds. exhibit excellent MLR inhibitory effect and are useful as inhibitors of allograft rejection in bone marrow and organ transplant or for the prevention and/or treatment of inflammatory diseases, organ-specific or organ-nonspecific autoimmune diseases, allergic diseases, chronic rheumatism, multiple sclerosis, inflammatory bowel disease, diabetes, glomerulonephritis, primary biliary liver cirrhosis, chronic active hepatitis, pernicious anemia, chronic thyroiditis, atrophic gastritis, myasthenia gravis, psoriasis, Sjoegren's syndrome, systemic lupus erythematosus, rhinitis, asthma, or atopic dermatitis. Thus, 0.1 mmol 4-hydrazino-2,6-bis(2-methoxyphenylamino)pyrimidine was dissolved in 1 mL ethanol, treated with 0.1 mmol 4-acetylpyridine, and stirred for 18 h to give 4-[N'-[1-(pyridin-4-yl)ethylidene]hydrazino]-2,6-bis(2-methoxyphenylamino)pyrimidine. N-methyl-4-[1-[[5-phenyl-2-phenylamino-6-[4-(pyridin-4-yl)pyrazol-1-yl]pyrimidin-4-yl]hydrazono]ethyl]benzenesulfonamide (II) inhibited MLR in human peripheral hemolymphocyte offered from two healthy people with IC50 of 1.0 ng/mL.
IT 850759-19-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine compds. as mixed lymphocyte reaction (MLR)

inhibitors)
RN 850759-19-2 CAPLUS
CN 4(1H)-Pyrimidinone, 5-phenyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:300260 CAPLUS
DN 142:373857
TI Preparation of 5-arylpyrimidines as anticancer agents
IN Zhang, Nan; Ayral-Kaloustian, Semiramis; Nguyen, Thai Hiep
PA Wyeth Holdings Corporation, USA
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030216	A1	20050407	WO 2004-US30682	20040917
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004275733	A1	20050407	AU 2004-275733	20040917
	CA 2539235	A1	20050407	CA 2004-2539235	20040917
	EP 1663241	A1	20060607	EP 2004-784529	20040917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004014736	A	20061121	BR 2004-14736	20040917
	CN 1871009	A	20061129	CN 2004-80031581	20040917
	JP 2007506746	T	20070322	JP 2006-528086	20040917
	US 2005075357	A1	20050407	US 2004-950375	20040924
	NO 2006001319	A	20060420	NO 2006-1319	20060323
PRAI	US 2003-505487P	P	20030924		
	WO 2004-US30682	W	20040917		

OS CASREACT 142:373857; MARPAT 142:373857
AB This invention relates to certain 5-arylpyrimidine compds. I [Z = NHCHR1R5, cycloalkyl; R = substituted Ph; X = Cl, Br; W1 = NHR6, N(CN)R6, aryl; R1 = H, alkyl; R5 = CF3, C2F5; R6 = alkyl] or a pharmaceutically acceptable salt thereof, and compns. containing said compds. or a pharmaceutically acceptable salt thereof, wherein said compds. are anti-cancer agents useful for the treatment of cancer in mammals (biol. data given). Over thirty examples describe the synthesis of compds. I. E.g., a multi-step synthesis of I [Z = NHCH2CF3; R = 2,4,6-F3C6H2; X = Cl; W1 = N(CN)Me], starting from 5,7-dichloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine and 2,2,2-trifluoroethylamine, was given. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of the compds. I or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises
administering to said mammal an effective amount of the compds. I and

pharmaceutically acceptable salts thereof.

IT 849600-48-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 5-arylpyrimidines as anticancer agents)

RN 849600-48-2 CAPLUS

CN 4-Pyrimidinamine, 6-chloro-2-(5-nitro-2-pyridinyl)-N-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



IT 585535-62-2P 585536-05-6P 849600-06-2P
849600-08-4P 849600-40-4P 849600-47-1P
849600-49-3P 849600-67-5P 849600-71-1P
849600-74-4P 849600-76-6P 849600-82-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-arylpyrimidines as anticancer agents)

RN 585535-62-2 CAPLUS

CN 4-Pyrimidinamine, 6-chloro-2-(2-pyridinyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-05-6 CAPLUS

CN 4-Pyrimidinamine, 6-chloro-2-(2-pyridinyl)-N-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 849600-06-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(4-pyridinyl)-N-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 849600-08-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(3-pyridinyl)-N-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 849600-40-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-2-(2-pyridinyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849600-47-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(4-methyl-2-pyridinyl)-N-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 849600-49-3 CAPLUS
CN 4-Pyrimidinamine, 2-(5-amino-2-pyridinyl)-6-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)



RN 849600-67-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(2-pyridinyl)-N-(2,2,2-trifluoro-1-methylethyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 849600-71-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-2-(2-pyridinyl)-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 849600-74-4 CAPLUS
CN 4-Pyrimidinamine, 2-(5-azido-2-pyridinyl)-6-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)



RN 849600-76-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(2-pyridinyl)-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849600-82-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-2-(2-pyridinyl)-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 849600-65-3P, 2-(5-Aminopyridin-2-yl)-6-chloro-N-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-arylpyrimidines as anticancer agents)

RN 849600-65-3 CAPLUS
CN 4-Pyrimidinamine, 2-(5-amino-2-pyridinyl)-6-chloro-N-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:205964 CAPLUS
DN 142:74474
TI Product class 12: pyrimidines
AU von Angerer, S.
CS Germany
SO Science of Synthesis (2004), 16, 379-572
CODEN: SSCYJ9
PB Georg Thieme Verlag
DT Journal; General Review
LA English
AB A review. Methods for preparing pyrimidines are reviewed including cyclization, ring transformation, aromatization and substituent modification.
IT 14757-06-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrimidines via cyclization, ring transformation, aromatization and substituent modification)
RN 14757-06-3 CAPLUS
CN 4-Pyrimidinamine, 5-(4-chlorophenyl)-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RE.CNT 856 THERE ARE 856 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:678804 CAPLUS
DN 139:197502
TI Preparation of 2-(2-pyridyl)-5-phenyl-6-aminopyrimidines as agricultural fungicides
IN Schieweck, Frank; Tormo i Blasco, Jordi; Grote, Thomas; Gypser, Andreas; Mueller, Bernd; Rheinheimer, Joachim; Rose, Ingo; Schaefer, Peter; Grammenos, Wassilios; Gewehr, Markus; Schwoegler, Anja; Blettner, Carsten; Ammermann, Eberhard; Strathmann, Siegfried; Lorenz, Gisela; Stierl, Reinhard
PA BASF Aktiengesellschaft, Germany
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA German

Appl pct

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070721	A1	20030828	WO 2003-EP1162	20030206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10210136	A1	20030918	DE 2002-10210136	20020308
	AU 2003210217	A1	20030909	AU 2003-210217	20030206
	EP 1504001	A1	20050209	EP 2003-742510	20030206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005107401	A1	20050519	US 2003-505146	20030206
	JP 2005523286	T	20050804	JP 2003-569628	20030206
PRAI	DE 2002-10207428	A	20020221		
	DE 2002-10210136	A	20020308		
	WO 2003-EP1162	W	20030206		

OS MARPAT 139:197502
AB Title compds. [I; R1 = halo, OH, cyano, oxo, NO2, amino, mercapto, (halo)alkyl, alkenyl, alkynyl, cycloalkyl, (halo)alkoxy, carboxyl, alkoxycarbonyl, carbamoyl, alkylaminocarbonyl, dialkylamincarbonyl, morpholinocarbonyl, pyrrolidinocarbonyl, alkylcarbonylamino, alkylamino, dialkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, hydroxysulfonyl, aminosulfonyl, (di)alkylaminosulfonyl; m = 0-4; R2 = H, halo, cyano, (halo)alkyl, alkoxy; R3, R4 = H, (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, cycloalkenyl, (halo)alkynyl, cycloalkynyl; or NR3R4 = (substituted) (O-, N- or S-interrupted) 5-6 membered ring; R5 = halo, (halo)alkyl; R6-R8 = H, halo, (halo)alkyl; R9 = H, halo, OH, cyano, alkyl, alkoxy, cycloalkoxy, haloalkoxy, alkoxycarbonyl, alkylaminocarbonyl], were prepared Thus, 3.3 g 4,6-dichloro-5-(2,4,6-trifluorophenyl)-2-(2-pyridyl)pyrimidine (preparation given) in DMF was stirred with 2.7 g isopropylamine for 24 h at 40° to give 3.05 g 6-chloro-5-(2,4,6-trifluorophenyl)-4-isopropylamino-2-(2-pyridyl)pyrimidine. The latter at 63 ppm showed 97% control of Alternaria solani on tomato.
IT 585535-49-5P 585535-52-0P 585535-53-1P
585535-54-2P 585535-55-3P 585535-56-4P
585535-57-5P 585535-58-6P 585535-59-7P
585535-60-0P 585535-61-1P 585535-62-2P

585535-63-3P 585535-64-4P 585535-65-5P
585535-66-6P 585535-67-7P 585535-68-8P
585535-69-9P 585535-70-2P 585535-71-3P
585535-72-4P 585535-73-5P 585535-74-6P
585535-75-7P 585535-76-8P 585535-77-9P
585535-78-0P 585535-79-1P 585535-80-4P
585535-81-5P 585535-82-6P 585535-83-7P
585535-84-8P 585535-85-9P 585535-86-0P
585535-87-1P 585535-88-2P 585535-89-3P
585535-90-6P 585535-91-7P 585535-92-8P
585535-93-9P 585535-94-0P 585535-95-1P
585535-96-2P 585535-97-3P 585535-98-4P
585535-99-5P 585536-00-1P 585536-01-2P
585536-02-3P 585536-03-4P 585536-04-5P
585536-05-6P 585536-06-7P 585536-07-8P
585536-08-9P 585536-09-0P 585536-10-3P
585536-11-4P 585536-12-5P 585536-13-6P
585536-14-7P 585536-15-8P 585536-16-9P
585536-17-0P 585536-18-1P 585536-19-2P
585536-20-5P 585536-21-6P 585536-22-7P
585536-23-8P 585536-24-9P 585536-25-0P
585536-26-1P 585536-27-2P 585536-28-3P
585536-30-7P 585536-32-9P 585536-34-1P
585536-36-3P 585536-38-5P 585536-40-9P
585536-42-1P 585536-44-3P 585536-46-5P
585536-47-6P 585536-48-7P 585536-49-8P
585536-50-1P 585536-51-2P 585536-52-3P
585536-53-4P 585536-54-5P 585536-55-6P
585536-56-7P 585536-57-8P 585536-58-9P
585536-59-0P 585536-60-3P 585536-61-4P
585536-62-5P 585536-63-6P 585536-64-7P
585536-65-8P 585536-66-9P 585536-67-0P
585536-68-1P 585536-69-2P 585536-70-5P
585536-71-6P 585536-72-7P 585536-73-8P
585536-74-9P 585536-75-0P 585536-76-1P
585536-77-2P 585536-78-3P 585536-79-4P
585536-80-7P 585536-81-8P 585536-82-9P
585536-83-0P 585536-84-1P 585536-85-2P
585537-10-6P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (pyridyl)(phenyl)aminopyrimidines as agricultural fungicides)

RN 585535-49-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(1-methylethyl)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-52-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-chloro-6-fluorophenyl)-N-ethyl-N-(2-methyl-2-propenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585535-53-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-chloro-6-fluorophenyl)-N-(1-methylethyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585535-54-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-chloro-6-fluorophenyl)-N-cyclopentyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585535-55-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-chloro-6-fluorophenyl)-N,N-diethyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585535-56-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-chloro-6-fluorophenyl)-2-(2-pyridinyl)-N-[(1S)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-57-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-chloro-6-fluorophenyl)-2-(2-pyridinyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-58-6 CAPLUS
CN Pyrimidine, 4-chloro-5-(2-chloro-6-fluorophenyl)-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585535-59-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N,N-diethyl-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-60-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1S)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-61-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-cyclopentyl-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-62-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(2-pyridinyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-63-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1S)-1,2-dimethylpropyl]-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-64-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(2,2-dimethylpropyl)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-65-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-66-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1R)-1,2-dimethylpropyl]-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-67-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(1-methylethyl)-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-68-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(6-methyl-2-pyridinyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-69-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N,N-diethyl-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-70-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(2,2-dimethylpropyl)-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-71-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-methyl-N-(1-methylethyl)-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-72-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-ethyl-N-(2-methylpropyl)-2-(6-methyl-2-

pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-73-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-ethyl-N-(2-methyl-2-propenyl)-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-74-6 CAPLUS
CN Morpholine, 4-[6-chloro-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 585535-75-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(1-methylpropyl)-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-76-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-cyclopentyl-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-77-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1R)-1,2-dimethylpropyl]-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-78-0 CAPLUS
CN Pyrimidine, 4-chloro-6-(4-methyl-1-piperidinyl)-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-79-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1S)-1,2-dimethylpropyl]-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-80-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1S)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-81-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(6-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-82-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(4-methyl-2-pyridinyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-83-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-methyl-N-(1-methylethyl)-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-84-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1S)-1,2-dimethylpropyl]-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-85-9 CAPLUS
CN Pyrimidine, 4-chloro-6-(4-methyl-1-piperidinyl)-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-86-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1S)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-87-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N,N-diethyl-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-88-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(2,2-dimethylpropyl)-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-89-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-ethyl-N-(2-methyl-2-propenyl)-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-90-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(1-methylpropyl)-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-91-7 CAPLUS

CN 4-Pyrimidinamine, 6-chloro-N-cyclopentyl-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-92-8 CAPLUS
CN Morpholine, 4-[6-chloro-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 585535-93-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1R)-1,2-dimethylpropyl]-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-94-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-95-1 CAPLUS
CN Pyrimidine, 4-methyl-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-96-2 CAPLUS
CN 4-Pyrimidinamine, N,N-diethyl-6-methoxy-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-97-3 CAPLUS
CN 4-Pyrimidinamine, 6-methyl-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-98-4 CAPLUS
CN 4-Pyrimidinamine, N-[(1R)-1,2-dimethylpropyl]-6-methyl-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585535-99-5 CAPLUS
CN 4-Pyrimidinamine, N,N-diethyl-6-methyl-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-00-1 CAPLUS
CN 4-Pyrimidinamine, 6-methyl-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1S)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-01-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-chloro-6-fluorophenyl)-2-(2-pyridinyl)-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 585536-02-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-ethyl-N-(2-methyl-2-propenyl)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-03-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(1-methylpropyl)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-04-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-methyl-N-(1-methylethyl)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-05-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(2-pyridinyl)-N-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-06-7 CAPLUS
CN Pyrimidine, 4-chloro-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-07-8 CAPLUS

CN Pyrimidine, 4-chloro-5-(2,6-difluoro-4-methoxyphenyl)-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-08-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N-(1-methylethyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-09-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N-[(1R)-1,2-dimethylpropyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-10-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-2-(2-pyridinyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-11-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N-(1-methylpropyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-12-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N-ethyl-N-(2-methyl-2-propenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-13-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N,N-diethyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-14-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N-ethyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-15-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-cyclopentyl-5-(2,6-difluoro-4-methoxyphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-16-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-N-[(1S)-1,2-dimethylpropyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-17-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluoro-4-methoxyphenyl)-2-(2-pyridinyl)-N-[(1S)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-18-1 CAPLUS
CN Phenol, 4-[4-chloro-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 585536-19-2 CAPLUS
CN Phenol, 4-[4-chloro-6-[(1-methylethyl)amino]-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 585536-20-5 CAPLUS
CN Phenol, 4-[4-chloro-6-[[(1R)-1,2-dimethylpropyl]amino]-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-21-6 CAPLUS
CN Phenol, 4-[4-chloro-2-(2-pyridinyl)-6-[[(1R)-1,2,2-trimethylpropyl]amino]-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-22-7 CAPLUS
CN Phenol, 4-[4-chloro-6-[ethyl(2-methyl-2-propenyl)amino]-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 585536-23-8 CAPLUS
CN Phenol, 4-[4-chloro-6-[[(1S)-1,2-dimethylpropyl]amino]-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-24-9 CAPLUS
CN Phenol, 4-[4-chloro-2-(2-pyridinyl)-6-[[(1S)-1,2,2-trimethylpropyl]amino]-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-25-0 CAPLUS
CN Phenol, 4-[4-chloro-6-(cyclopentylamino)-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 585536-26-1 CAPLUS
CN Phenol, 4-[4-chloro-6-[methyl(2-methylpropyl)amino]-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 585536-27-2 CAPLUS
CN Phenol, 4-[4-[bis(2-methylpropyl)amino]-6-chloro-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 585536-28-3 CAPLUS
CN Phenol, 4-[4-chloro-6-[ethyl(2-methylpropyl)amino]-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 585536-30-7 CAPLUS
CN Pyrimidine, 4-chloro-5-(2,6-difluorophenyl)-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-32-9 CAPLUS

CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluorophenyl)-N,N-diethyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-34-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluorophenyl)-N-[(1S)-1,2-dimethylpropyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-36-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluorophenyl)-N-(1-methylethyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-38-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,6-difluorophenyl)-N-[(1R)-1,2-dimethylpropyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-40-9 CAPLUS
CN Pyrimidine, 4-chloro-5-(2,4-dimethylphenyl)-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-42-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,4-dimethylphenyl)-N-(1-methylethyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-44-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-cyclopentyl-5-(2,4-dimethylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-46-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,4-dimethylphenyl)-N-[(1S)-1,2-dimethylpropyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-47-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,4-dimethylphenyl)-N-[(1R)-1,2-dimethylpropyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-48-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,4-dimethylphenyl)-N-ethyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-49-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,4-dimethylphenyl)-N,N-diethyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-50-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2,4-dimethylphenyl)-2-(2-pyridinyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-51-2 CAPLUS
CN Benzonitrile, 4-[4-chloro-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)-5-pyrimidinyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 585536-52-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-fluoro-4-methylphenyl)-N-(1-methylethyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-53-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1S)-1,2-dimethylpropyl]-5-(2-fluoro-4-methylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-54-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1R)-1,2-dimethylpropyl]-5-(2-fluoro-4-methylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-55-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-fluoro-4-methylphenyl)-2-(2-pyridinyl)-N-[(1S)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-56-7 CAPLUS
CN Pyrimidine, 4-chloro-5-(2-fluoro-4-methylphenyl)-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-57-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-fluoro-4-methylphenyl)-N-(1-methylpropyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-58-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N,N-diethyl-5-(2-fluoro-4-methylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-59-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-cyclopentyl-5-(2-fluoro-4-methylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-60-3 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-ethyl-5-(2-fluoro-4-methylphenyl)-N-(2-methyl-2-propenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-61-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(2-fluoro-4-methylphenyl)-2-(2-pyridinyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 585536-62-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(4-fluoro-2-methylphenyl)-N-(1-methylethyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-63-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(4-fluoro-2-methylphenyl)-2-(2-pyridinyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 585536-64-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1S)-1,2-dimethylpropyl]-5-(4-fluoro-2-methylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-65-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1R)-1,2-dimethylpropyl]-5-(4-fluoro-2-methylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-66-9 CAPLUS
CN Pyrimidine, 4-chloro-5-(4-fluoro-2-methylphenyl)-6-(4-methyl-1-piperidinyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-67-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(4-fluoro-2-methylphenyl)-N-(1-methylpropyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-68-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N,N-diethyl-5-(4-fluoro-2-methylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-69-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-cyclopentyl-5-(4-fluoro-2-methylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 585536-70-5 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-5-(4-fluoro-2-methylphenyl)-2-(2-pyridinyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-71-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-ethyl-N-(2-methylpropyl)-2-(4-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-72-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1S)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-73-8 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N,N-diethyl-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-74-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(2,2-dimethylpropyl)-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-75-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-methyl-N-(1-methylethyl)-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-76-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-ethyl-N-(2-methylpropyl)-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-77-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-ethyl-N-(2-methyl-2-propenyl)-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-78-3 CAPLUS
CN Morpholine, 4-[6-chloro-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 585536-79-4 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(1-methylpropyl)-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-80-7 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1S)-1,2-dimethylpropyl]-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-81-8 CAPLUS
CN Pyrimidine, 4-chloro-6-(4-methyl-1-piperidinyl)-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-82-9 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-cyclopentyl-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585536-83-0 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-84-1 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-[(1R)-1,2-dimethylpropyl]-2-(3-methyl-2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585536-85-2 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-2-(3-methyl-2-pyridinyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585537-10-6 CAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-ethyl-5-(4-fluoro-2-methylphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



IT 585535-50-8P 585535-51-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyridyl)(phenyl)aminopyrimidines as agricultural fungicides)

RN 585535-50-8 CAPLUS

CN 4(1H)-Pyrimidinone, 6-hydroxy-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 585535-51-9 CAPLUS

CN Pyrimidine, 4,6-dichloro-2-(2-pyridinyl)-5-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:417751 CAPLUS
DN 139:6885
TI Preparation of substituted indolizine-like compounds to inhibit TNF-α production
IN Cai, Guolin; Chau, Jennifer N.; Dominguez, Celia; Rishton, Gilbert M.; Lu, Yuelie
PA Amgen Inc., USA
SO PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003044021	A2	20030530	WO 2002-US36699	20021116
	WO 2003044021	A3	20031218		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003195221	A1	20031016	US 2002-298205	20021115
	US 6921762	B2	20050726		
	CA 2466072	A1	20030530	CA 2002-2466072	20021116
	AU 2002352722	A1	20030610	AU 2002-352722	20021116
	EP 1448564	A2	20040825	EP 2002-789671	20021116
	EP 1448564	B1	20060419		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005518358	T	20050623	JP 2003-545658	20021116
	AT 323705	T	20060515	AT 2002-789671	20021116
	PT 1448564	T	20060630	PT 2002-789671	20021116
	ES 2262879	T3	20061201	ES 2002-2789671	20021116
PRAI	US 2001-332447P	P	20011116		
	US 2002-298205	A1	20021115		
	WO 2002-US36699	W	20021116		

OS MARPAT 139:6885
AB Title compds. I [X = CR2, N; R1-2 = ZY, Y provided that the total number of (hetero)aryl, cycloalkyl and heterocyclyl radicals in R1-2 = 0-3; U, V, W = CR6, N provided when U = N, V = CR6; R6 = H, halo, alkyl, alkoxy, etc.; Z = alk(en/yn)yl, heterocyclyl, etc.; Y = H, halo, NO2, etc.; R11 = (hetero)aryl; R12 = N-heteroaryl] are prepared For instance, Et [4-fluorophenyl]acetate is reacted with 4-cyanopyridine, MeNCS and MeI (DMF, KOBu-t/HOBu-t) to give 5-(4-fluorophenyl)-3-methyl-2-(methylthio)-6-(pyridin-4-yl)-3H-pyrimidin-4-one. This intermediate is treated with POCl3 (120°, 16 h) and the product treated with hydrazine (EtOH, 70°) followed by (S)-3-phenylpropane-1,2-diamine (preparation given) to give II. Selected example compds. exhibit activities in the THP1 cell assay (LPS induced TNF release) with IC50 ≤ 20 μM. I are effective for treatment of TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases and other maladies, such as cancer, pain and diabetes.
IT 534601-65-5P, 2,6-Bis(2-chloropyridin-4-yl)-3-methyl-5-(3-methylphenyl)-3H-pyrimidin-4-one
RL: BYP (Byproduct); PREP (Preparation)

(preparation of substituted indolizine-like compds. to inhibit TNF-α production)

RN 534601-65-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2,6-bis(2-chloro-4-pyridinyl)-3-methyl-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)



IT 534601-86-0, 2,6-Bis[2-chloro-4-pyridyl]-4-chloro-5-(3-methylphenyl)pyrimidine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted indolizine-like compds. to inhibit TNF-α production)

RN 534601-86-0 CAPLUS

CN Pyrimidine, 4-chloro-2,6-bis(2-chloro-4-pyridinyl)-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:877027 CAPLUS
DN 138:280306
TI Synthesis and Characterization of Some Ruthenium Mixed-Ligand Complexes
AU Shawakfeh, K. Q.; Al-Rawashdeh, N. A. F.; Khader, S.
CS Department of Applied Chemical Science, Jordan University of Science and Technology, Irbid, 22110, Jordan
SO Russian Journal of Coordination Chemistry (Translation of Koordinatsionnaya Khimiya) (2002), 28(11), 789-793
CODEN: RJCCEY; ISSN: 1070-3284
PB MAIK Nauka/Interperiodica Publishing
DT Journal
LA English
OS CASREACT 138:280306
AB The complexation reaction of trans-[RuCl2(Dpte)2] (Dpte = bis(phenylthio)ethane) with mixed diimine ligands 2,2 -bipyridine, pyridylquinoline, 4,6-dichloro-2-(2-pyridyl)pyrimidine, 4,6-dichloro-5-methyl-2-(2-pyridyl)pyrimidine, and 4,6-dichloro-5-phenyl-2-(2-pyridyl)pyrimidine produces new Ru(II) mixed-ligand complexes. These complexes exhibit maximum photo- and chemical stability and high absorptivity. The above complexes were characterized using IR, 1H and 13C NMR, electronic absorption spectroscopy, and elemental anal.
IT 10198-78-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(for preparation of ruthenium bis(phenylthio)ethane polyamine complex)
RN 10198-78-4 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-phenyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Claim 27 requires 2 sub. on the ring.

L12 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:862384 CAPLUS
DN 138:255192
TI Carbon-carbon bond construction at the 2-position of polysubstituted pyrimidinones
AU Zhang, Dawei; Sham, Kelvin; Cao, Guo-Qiang; Hungate, Randall; Dominguez, Celia
CS Department of Small Molecule Drug Discovery, AMGEN Inc., Thousand Oaks, CA, 91320, USA
SO Tetrahedron Letters (2002), 43(49), 8901-8903
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 138:255192
AB A novel synthetic method to introduce a carbon-carbon bond at the 2-position of pyrimidinones via nucleophilic addition of Grignard reagents to 2-cyano pyrimidinones at ambient conditions is disclosed. This unique approach leads to the preparation of such biol. important mols. as polysubstituted pyrimidinones in good to excellent yields.
IT 502421-29-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of polysubstituted pyrimidinones via nucleophilic addition of Grignard reagents to 2-cyano pyrimidinones)
RN 502421-29-6 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 4-[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]-2-pyrimidinyl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:814110 CAPLUS
DN 137:325425
TI Preparation of sulfonylaminopyrimidines as endothelin receptor antagonists.
IN Bolli, Martin; Boss, Christoph; Clozel, Martine; Fischli, Walter; Weller, Thomas
PA Actelion Pharmaceuticals Ltd., Switz.
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002083650	A1	20021024	WO 2002-EP3947	20020409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI WO 2001-EP4169 W 20010411
OS MARPAT 137:325425
AB Title compds. [I; R1 = aryl, heteroaryl; R2 = alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; R3 = Ph, mono, di- or trisubstituted Ph substituted with alkyl, alkenyl, alkyloxy, CF3, halo, alkylthio, hydroxyalkyl, cyano, CO2H, alkyloxycarbonyl, alkanoyl, CHO; R4 = H, CF3, alkyl, alkylamino, alkyloxy, alkylsulfinyl, alkylthio, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxyalkyl, hydroxyalkylamino, alkylaminoalkyl, amino, aryl, heteroaryl, heterocyclyl, heterocyclylalkoxy, heterocyclyloxy, heterocyclylamino, heterocyclylalkylamino, heterocyclylthio, heterocyclylalkylthio, heterocyclylalkyl, cycloalkyl, cycloalkyloxy, cycloalkylalkoxy, cycloalkylamino, cycloalkylalkylamino, cycloalkylalkyl, cycloalkylsulfinyl; A = CH2, CH2CH2, CH2CH2CH2, CH:CH, C.tplbond.C; T = O, S; X = O, S, CH2, bond; Y = O, S, NH; Q = (CH2)k, CH2C.tplbond.CCH2; k = 2, 3, 4; Z = O, NH], were prepared Thus, 2-picolinic acid azide and DMAP in CHCl3 were stirred for 1 h at 70°; 2-phenylethenesulfonic acid [6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]amide (preparation given) was added and the resulting solution was stirred for 16 h at 70° to give pyridin-2-ylcarbamic acid 2-[5-(2-methoxyphenoxy)-6-(2-phenylethenesulfonylamino)-2-pyridin-4-ylpyrimidin-4-yloxy]ethyl ester. I inhibited binding of endothelin to ETA receptors with IC50 = 1-14 nM.
IT 346671-53-2P 346671-54-3P 473537-11-0P
473537-12-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of sulfonylaminopyrimidines as endothelin receptor antagonists)
RN 346671-53-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-hydroxy-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 346671-54-3 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 473537-11-0 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)-2-(1-oxido-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 473537-12-1 CAPLUS
CN Ethenesulfonamide, N-[6-chloro-5-(4-methylphenyl)-2-(1-oxido-4-pyridinyl)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:770446 CAPLUS
DN 138:128340
TI Luminescence quenching of mixed-ligand ruthenium(II) complexes by different quenchers
AU Al-Rawashdeh, Nathir A. F.; Shawakfeh, Khaled; Khadir, Sumaia
CS Department of Applied Chemical Sciences, Jordan University of Science and Technology, Irbid, 22110, Jordan
SO Acta Chimica Slovenica (2002), 49(3), 425-436
CODEN: ACSLE7; ISSN: 1318-0207
PB Slovenian Chemical Society
DT Journal
LA English
AB The effect of ionic strength and acidity (pH) on the luminescence quenching of the excited states of a number of mixed-ligand Ru(II) complexes were studied. The mixed-ligand Ru(II) complexes of diphenyl-thioethylene (dpte); 2,2'-bipyridine (bpy), 2-(2-pyridyl)-quinoline (pyq); 4,6-dichloro-2-(2-pyridyl)pyrimidine (dcppm); 4,6-dichloro-5-methyl-2-(2-pyridyl)pyrimidine (dcmppm); 4,6-dichloro-5-phenyl-2-(2 pyridyl)pyrimidine (dcpppm) with three quenchers: N,N,N',N'-tetramethyl-p-phenlyenediamine (TMPD2+), Me viologen (Mv2+), and EDTA were used to study the effect of acidity. Whereas, for the effect of ionic strength, [Ru(dpte)2(dcpppm)]2+ /EDTA system was used. The quenching rate constant (kq) increases with decreasing the ionic strength, while pH has the opposite effect. The quenching of mixed-ligand Ru(II) complexes by TMPD2+ in aqueous solns. is dynamic and static in nature.
IT 10198-78-4
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
(luminescence quenching of mixed-ligand ruthenium(II) complexes by different quenchers)
RN 10198-78-4 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-phenyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Claim 27 requires 2 Sub.

L12 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:521730 CAPLUS
DN 137:93766
TI Preparation of novel pyrimidine-sulfamides as endothelin receptor antagonists
IN Bolli, Martin; Boss, Christoph; Fischli, Walter; Clozel, Martine; Weller, Thomas
PA Actelion Pharmaceuticals Ltd., Switz.
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053557	A1	20020711	WO 2001-EP14182	20011204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2431675	A1	20020711	CA 2001-2431675	20011204
	EP 1345920	A1	20030924	EP 2001-989570	20011204
	EP 1345920	B1	20060412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001016237	A	20030930	BR 2001-16237	20011204
	JP 2004517855	T	20040617	JP 2002-554676	20011204
	CN 1524079	A	20040825	CN 2001-820481	20011204
	NZ 525614	A	20050324	NZ 2001-525614	20011204
	AT 323079	T	20060415	AT 2001-989570	20011204
	EP 1693372	A1	20060823	EP 2006-7371	20011204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	PT 1345920	T	20060831	PT 2001-989570	20011204
	ES 2260318	T3	20061101	ES 2001-1989570	20011204
	ZA 2003003695	A	20040813	ZA 2003-3695	20030513
	US 2004077670	A1	20040422	US 2003-433041	20030527
	US 7094781	B2	20060822		
	NO 2003002699	A	20030613	NO 2003-2699	20030613
	US 2006178365	A1	20060810	US 2006-400697	20060407
PRAI	WO 2000-EP12890	W	20001218		
	EP 2001-989570	A3	20011204		
	WO 2001-EP14182	W	20011204		
	US 2003-433041	A1	20030527		

OS MARPAT 137:93766
AB The title compds. [I; R1 = aryl, arylalkyl, heteroaryl, etc.; or NR1R6 = heterocyclyl; R2 = Me, CH2(tetrahydrofuran-2-yl), etc.; R3 = aryl, heteroaryl; R4 = H, CF3, alkyl, etc.; R6 = H, alkyl; X = O, S, CH2, a bond] were prepared Thus, treating 4-isopropylphenylsulfamic acid [6-chloro-5-(2-methoxyphenoxy)-2-(4-pyridyl)pyrimidin-4-yl]amide (5-step synthesis given) with NaH in MeOH and THF afforded I [R1 = 4-(iso-Pr)C6H4; R2 = Me; R3 = 2-MeOC6H4; R4 = 4-pyridyl; R6 = H; X = O] which showed IC50 of 721 nM and 8429 nM against ETA and ETB receptor binding, resp.
IT 346671-53-2P 346671-54-3P 441797-31-5P
441797-37-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine-sulfamides as endothelin receptor antagonists)

RN 346671-53-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-hydroxy-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 346671-54-3 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441797-31-5 CAPLUS
CN Sulfamide, N-[6-chloro-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441797-37-1 CAPLUS
CN Sulfamide, N-[6-chloro-5-(4-chlorophenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:240744 CAPLUS
DN 136:263176
TI Preparation of novel arylalkylsulfonamides as endothelin receptor antagonists
IN Weller, Thomas; Bolli, Martin; Boss, Christoph; Clozel, Martine; Fischli, Walter
PA Actelion Pharmaceuticals Ltd., Switz.
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024665	A1	20020328	WO 2001-EP9894	20010828
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2423351	A1	20020328	CA 2001-2423351	20010828
	AU 2002012171	A5	20020402	AU 2002-12171	20010828
	EP 1322624	A1	20030702	EP 2001-980288	20010828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001014082	A	20030722	BR 2001-14082	20010828
	HU 200303364	A2	20040301	HU 2003-3364	20010828
	JP 2004509874	T	20040402	JP 2002-529075	20010828
	NZ 524172	A	20040924	NZ 2001-524172	20010828
	CN 1633418	A	20050629	CN 2001-815896	20010828
	NO 2003001332	A	20030324	NO 2003-1332	20030324
	ZA 2003002292	A	20040630	ZA 2003-2292	20030324
	US 2004102464	A1	20040527	US 2003-381568	20030325
	US 7091201	B2	20060815		
PRAI	WO 2000-EP9327	W	20000925		
	WO 2001-EP9894	W	20010828		

OS MARPAT 136:263176
AB Title compds. [I; R1 = C6H5, 2-thienyl, 2-pyridyl; n = 1, 2, 3; R2 = (un)substituted-2-pyrimidyl, (un)substituted-2-pyridyl, (un)substituted-Ph; m = 2, 3; X = R3, OR4; R3 = substituted-phenyl; R4 = 2-CH3OC6H4, 3-CH3OC6H4; R5 = H, 2-pyrimidyl, 4-pyridyl, 4-morpholinyl, 2-pyrazinyl] and pharmaceutically acceptable salts are prepared and their use as active ingredients in the preparation of pharmaceutical compns. are disclosed. The invention also concerns related aspects including processes for the preparation of the compds., pharmaceutical compns. containing one or more of those compds., require mixed ETA and ETB blocking for treatment, and especially their use as endothelin receptor antagonists. Thus, the title compound II was prepared from 2-(p-tolyl)malonic acid di-Et ester, formamidine, 2-phenylethanesulfonyl chloride, and 2-chloro-pyrimidine via cyclization, chloronation, sulfonation, displacement, etc.
IT 346671-53-2P 346671-54-3P 405308-03-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of arylalkylsulfonamides as endothelin receptor antagonists)

RN 346671-53-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-hydroxy-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 346671-54-3 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 405308-03-4 CAPLUS
CN Benzeneethanesulfonamide, N-[6-chloro-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:798218 CAPLUS
DN 135:331440
TI Preparation of substituted sulfonylaminopyrimidines as endothelin receptor antagonists
IN Boss, Christoph; Bolli, Martin; Clozel, Martine; Fischli, Walter; Weller, Thomas
PA Actelion Pharmaceuticals Ltd., Switz.
SO PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001081338	A1	20011101	WO 2001-EP4133	20010411

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI WO 2000-EP3692 W 20000425
OS MARPAT 135:331440
AB The present invention relates to novel substituted pyrimidines I (e.g. rac-5-isopropyl-N-[5-(2-methoxyphenoxy)-2-(4-pyridyl)-6-(tetrahydrofuran-2-ylmethoxy)-4-pyrimidinyl]-2-pyridinesulfonamide) and pharmaceutically acceptable salts thereof and their use as active ingredients in the preparation of pharmaceutical compns. The invention also concerns related aspects including processes for the preparation of the compds., pharmaceutical compns. containing one or more I and especially their use as endothelin receptor antagonists. In I: R1 = aryl; aryl-lower alkyl; aryl-lower alkenyl; heteroaryl; heteroaryl-lower alkyl. R2 = H; halogen; trifluoromethyl; lower alkyl; lower alkylamino; lower alkyloxy; lower alkylsulfono; lower alkylsulfinyl; lower alkylthio; lower alkylthio-lower alkyl; hydroxy-lower alkyl; hydroxy-lower alkyloxy; lower alkyloxy-lower alkyl; lower alkyloxy-lower alkyloxy; hydroxy-lower alkyloxy-lower alkyl; hydroxy-lower alkyloxy-lower alkyloxy; lower alkyloxy-lower alkyloxy-lower alkyloxy; hydroxy-lower alkylamino; lower alkylamino-lower alkyl; amino; di-lower alkylamino; [N-(hydroxy-lower alkyl)-N-(lower alkyl)]amino; aryl; arylamino; aryl-lower alkylamino; arylthio; aryl-lower alkylthio; aryloxy. Also, R2 = aryl-lower alkyloxy; aryl-lower alkyl; arylsulfinyl; heteroaryl; heteroaryloxy; heteroaryl-lower alkyloxy; heteroarylamino; heteroaryl-lower alkylamino; heteroaryl-lower alkylthio; heteroaryl-lower alkyl; heteroarylsulfinyl; heterocyclyl; heterocyclyl-lower alkyloxy; heterocyclyloxy; heterocyclylamino; heterocyclyl-lower alkylamino; heterocyclylthio; heterocyclyl-lower alkylthio; heterocyclyl-lower alkyl; heterocyclylsulfinyl; cycloalkyl; cycloalkyloxy; cycloalkyl-lower alkyloxy; cycloalkylamino; cycloalkyl-lower alkylamino; cycloalkylthio; cycloalkyl-lower alkyl; cycloalkylsulfinyl; alkyloxycarbonyl; carboxy; cycloalkyl-lower alkylthio; cyano; aminocarbonyl. R3 = phenyl; mono, di- or trisubstituted Ph substituted with lower alkyl, lower alkenyl, lower alkyloxy, amino, lower alkylamino, amino-lower alkyl, trifluoromethyl, trifluoromethoxy, halogen, lower alkylthio, hydroxy, hydroxy-lower alkyl, cyano, carboxy, alkoxycarbonyl, lower alkanoyl, formyl; benzofuranyl; aryl; heteroaryl. X = O; S; NH; CH2 or a bond; R4 = N(CH2)2Z(CH2)2 (Z = = O, imino, S, SO, or SO2) and substituted alkoxy as specified in the

claims. Ninety-two example prepns. are included, but the methods of preparation are not claimed. IC50 (concentration of antagonist inhibiting 50% of the specific binding of ET-1) values were determined for some of the claimed compds. and were as low as 6 nM (rac-5-methylpyridine-2-sulfonic acid [5-(2-methoxyphenoxy)-6-(tetrahydrofuran-2-ylmethoxy)-2-[2-(5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)pyridin-4-yl]pyrimidin-4-yl]amide). Also, pA2 (neg. value of logarithm of antagonist concentration that induces 2-fold shift in concentration of endothelin needed to get half-maximal contraction on isolated rat aortic rings or rat tracheal rings) are reported for 5 I.

IT 346671-53-2P, 2-Pyridin-4-yl-5-p-tolylpyrimidine-4,6-diol
346671-54-3P, 4,6-Dichloro-2-(4-pyridyl)-5-(p-tolyl)pyrimidine
346671-55-4P, 5-Isopropyl-N-[6-chloro-5-(p-tolyl)-2-(4-pyridyl)-4-pyrimidinyl]-2-pyridinesulfonamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted sulfonylaminopyrimidines as endothelin receptor antagonists)

RN 346671-53-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-hydroxy-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



requires 2 sub

RN 346671-54-3 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 346671-55-4 CAPLUS
CN 2-Pyridinesulfonamide, N-[6-chloro-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 370105-98-9P, Rac-5-isopropyl-N-[5-(p-tolyl)-2-(4-pyridyl)-6-(tetrahydrofuran-2-ylmethoxy)-4-pyrimidinyl]-2-pyridinesulfonamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted sulfonylaminopyrimidines as endothelin receptor antagonists)

RN 370105-98-9 CAPLUS

CN 2-Pyridinesulfonamide, 5-(1-methylethyl)-N-[5-(4-methylphenyl)-2-(4-pyridinyl)-6-[(tetrahydro-2-furanyl)methoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:798215 CAPLUS
DN 135:344498
TI Preparation of N-(pyrimidin-4-yl) (hetero)arylsulfonamides having endothelin-antagonist activity
IN Bolli, Martin; Boss, Christoph; Clozel, Martine; Fischli, Walter; Weller, Thomas
PA Actelion Pharmaceuticals Ltd., Switz.
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001081335	A1	20011101	WO 2001-EP4136	20010411

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI WO 2000-EP3585 W 20000420
OS MARPAT 135:344498
AB The title compds. [I; R1 = (hetero)aryl; R2 = (CH2)nCRa:CRbRc, (CH2)nC.tplbond.CRb; R3 = (un)substituted Ph, benzofuranyl, (hetero)aryl; R4 = H, halo, CF3, etc.; X = O, S, NH, CH2, a bond; Ra, Rc = H, alkyl; Rb = H, alkyl, aryl, etc.; n = 1-6], useful as endothelin receptor antagonists, were prepared Thus, treatment of propargyl alc. with NaH in THF followed by addition of the pyrimidine II [R = Cl] (multi-step preparation given) afforded the title compound II [R = OCH2C.tplbond.CH] which showed IC50 of 125 nM and of 823 nM against endothelin ETA and ETB binding to membranes from CHO cells, resp.
IT 370566-14-6P 370567-46-7P 370567-47-8P
370567-48-9P 370567-49-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(pyrimidin-4-yl) (hetero)arylsulfonamides having endothelin-antagonist activity)
RN 370566-14-6 CAPLUS
CN 2-Pyridinesulfonamide, 5-(1-methylethyl)-N-[5-(4-methylphenyl)-6-(2-propenyloxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 370567-46-7 CAPLUS
CN 2-Pyridinesulfonamide, N-[6-(2-butynyloxy)-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 370567-47-8 CAPLUS
CN 2-Pyridinesulfonamide, 5-(1-methylethyl)-N-[5-(4-methylphenyl)-6-(2-pentenyloxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 370567-48-9 CAPLUS
CN 2-Pyridinesulfonamide, N-[6-(2-butenyloxy)-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 370567-49-0 CAPLUS
CN 2-Pyridinesulfonamide, N-[6-(3-butenyloxy)-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 346671-53-2P, 4,6-Dihydroxy-2-(4-pyridyl)-5-(p-tolyl)pyrimidine
346671-54-3P, 4,6-Dichloro-2-(4-pyridyl)-5-(p-tolyl)pyrimidine
346671-55-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(pyrimidin-4-yl) (hetero)arylsulfonamides having endothelin-antagonist activity)

RN 346671-53-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-hydroxy-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 346671-54-3 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 346671-55-4 CAPLUS
CN 2-Pyridinesulfonamide, N-[6-chloro-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:472681 CAPLUS
DN 135:76885
TI Preparation of 4-(4-pyrimidinyloxy)-2-butyn-1-ol derivatives as endothelin receptor antagonists
IN Bolli, Martin; Boss, Christoph; Clozel, Martine; Fischli, Walter
PA Actelion Pharmaceuticals Ltd., Switz.
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001046156	A1	20010628	WO 2000-EP12743	20001214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2389479	A1	20010628	CA 2000-2389479	20001214
	AU 2001035367	A5	20010703	AU 2001-35367	20001214
	EP 1244637	A1	20021002	EP 2000-991788	20001214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000016241	A	20021112	BR 2000-16241	20001214
	HU 200204168	A2	20030428	HU 2002-4168	20001214
	JP 2003518102	T	20030603	JP 2001-547067	20001214
	ZA 2002003796	A	20030813	ZA 2002-3796	20020513
	NO 2002002971	A	20020620	NO 2002-2971	20020620
	US 2003087920	A1	20030508	US 2002-168752	20020624
	US 6720322	B2	20040413		
PRAI	WO 1999-EP10276	W	19991222		
	WO 2000-EP12743	W	20001214		

OS MARPAT 135:76885
AB The title butynediol derivs. (I) [wherein R1 = (un)substituted Ph, heterocyclyl, 2-pyridyl, benzyl, or (hetero)aryl; R2 = H, alkyl, CF3 or (un)substituted Ph, heterocyclyl, heteroaryl, benzyl, 2-pyrimidyl, (hetero)aryl, (thio)carbamoyl, (thio)acyl, etc.; R3 = H, alkyl, or (un)substituted Ph, benzofuranyl, or heteroaryl; R4 = H, halo, CF3, alkyl, alkoxy(alkyl), alkylthio(alkyl), hydroxyalkyl, aminoalkyl(alkyl), aryl(alkyl), arylamino, arylthio, aryloxy, heteroaryl, heterocyclyl, or (un)substituted amino or Ph, etc.; X = O, S, NH, or a bond; or the enantiomers,diastereomers, and diastereomeric racemates thereof] were prepared as endothelin (ET) receptor antagonists. For example, cycloaddn. of 4-amidinopyridine•HCl to di-Me (o-methoxyphenoxy)malonate (preparation of starting materials given) to give the dihydroxypyrimidine, chlorination using PCl5, addition of 5-isopropylpyridine-2-sulfonamide•K, and reaction with 2-butyne-1,4-diol afforded II. The latter inhibited the binding of [125I]endothelin-1 to microsomal membranes from recombinant CHO cells expressing recombinant ETA or ETB receptors with IC50 values of 26 nM and 77 nM, resp. I are useful for the treatment of endothelin-related disorders, such as circulatory disorders, proliferative disorders, migraine, asthma, and inflammatory disorders (no data).
IT 346671-53-2P 346671-54-3P 346671-55-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate; preparation of 4-(4-pyrimidinyloxy)-2-butyn-1-ol endothelin receptor antagonists by reaction of chloropyrimidines with 2-butyne-1,4-diols or hydroxy-protected 2-butyne-1,4-diols)

RN 346671-53-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-hydroxy-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 346671-54-3 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-(4-methylphenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 346671-55-4 CAPLUS
CN 2-Pyridinesulfonamide, N-[6-chloro-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 346671-56-5P 346671-90-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(4-pyrimidinyloxy)-2-butyn-1-ol endothelin receptor antagonists by reaction of chloropyrimidines with 2-butyne-1,4-diols or hydroxy-protected 2-butyne-1,4-diols)

RN 346671-56-5 CAPLUS
CN 2-Pyridinesulfonamide, N-[6-[(4-hydroxy-2-butynyl)oxy]-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 346671-90-7 CAPLUS
CN 2-Pyridinesulfonamide, N-[6-[[4-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-2-butynyl]oxy]-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:531662 CAPLUS
DN 133:120343
TI Preparation of arylpyrimidinones and analogs as drugs
IN Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
PA Amgen Inc., USA
SO U.S., 92 pp., Cont.-in-part of U.S. Ser. No. 976,053, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6096753	A	20000801	US 1997-985346	19971204
	ZA 9710727	A	19980612	ZA 1997-10727	19971128
	CN 1246857	A	20000308	CN 1997-181558	19971204
	TW 520362	B	20030211	TW 1997-86118244	19971204
	EP 1314731	A2	20030528	EP 2002-27704	19971204
	EP 1314731	A3	20040102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, AL				
	EP 1314732	A2	20030528	EP 2002-27705	19971204
	EP 1314732	A3	20040102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
	ZA 9710911	A	19980605	ZA 1997-10911	19971205
	US 6420385	B1	20020716	US 2000-504509	20000215
	US 6410729	B1	20020625	US 2000-598740	20000621
	US 2003069425	A1	20030410	US 2002-117552	20020403
	US 6610698	B2	20030826		
	US 2003073704	A1	20030417	US 2002-128271	20020423
	US 6649604	B2	20031118		
PRAI	US 1996-32128P	P	19961205		
	US 1997-50950P	P	19970613		
	US 1997-976053	B2	19971121		
	US 1997-976054	A	19971121		
	EP 1997-954778	A3	19971204		
	US 1997-984774	B1	19971204		
	US 1997-985346	A3	19971204		
	US 2000-504509	A3	20000215		
	US 2000-598740	A3	20000621		

OS MARPAT 133:120343
AB Title compds. [e.g., I; Z = N or CR2; R1,R2 = R or Z1R; R = H, halo, alkoxy(carbonyl), amino(carbonyl or sulfonyl), etc.; R3 = Z1R; R4,R5 = (un)substituted (hetero)aryl; X = O, S, (un)substituted imino; Z1 = alkylene, heterocyclylene, (hetero)arylene, etc.] were prepared as agents for reduction of, e.g., TNF-α levels. Thus, 4-FC6H4CH2CO2Et was acylated by Et isonicotinate and the product cyclocondensed with (H2N)2CS to give, after N-methylation, I (R3 = Me, R4 = C6H4F-4, R5 = 4-pyridyl, X = O)(II; R1 = SH) which was aminated by 2-FC6H4CH(NH2)CH2CH2NH2 to give II [R1 = NHCH2CH2CH(NH2)C6H4F-2]. Data for biol. activity of I were given.
IT 20091-23-0P 208653-63-8P 208653-66-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrimidinones and analogs as drugs)
RN 20091-23-0 CAPLUS
CN 4(1H)-Pyrimidinone, 5-phenyl-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 208653-63-8 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 208653-66-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2,6-di-3-pyridinyl- (9CI) (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:796170 CAPLUS
DN 132:188849
TI Synthesis, physical and photophysical properties of Ru(II) pyridyl-pyrimidine and pyridyl-pyrimidinone complexes: effect of substituents on the pyrimidine ring
AU Xue, W.-M.; Perez, W. J.; Rillema, D. P.
CS Department of Chemistry, Wichita State University, Wichita, KS, USA
SO Inorganica Chimica Acta (1999), 296(1), 114-126
CODEN: ICHAA3; ISSN: 0020-1693
PB Elsevier Science S.A.
DT Journal
LA English
AB [Ru(bpy)2((EtO)2pypmR)]2+ (R = H, Me and pypm = 2-(2-pyridyl)pyrimidine) forms by ethoxide substitution of 4,6-halo groups when Ru(bpy)2CO3·2H2O reacts with 4,6-dihalo-2-(2-pyridyl)pyrimidine in EtOH. When these ligands react with Ru(bpy)2Cl2·2H2O in acetone, [Ru(bpy)2(ClpypnR)]+ (R = H, Me, Ph and pypn = 2-(2-pyridyl)pyrimidinone) forms by a hydrolytic reaction. The complexes give rise to metal-to-ligand charge transfer (MLCT) absorptions in the 320-480 nm region and π π* transitions <300 nm. The lowest energy dπ π* absorptions of [Ru(bpy)2(ClpypnR)]+ shift to the red region of the spectrum when compared with those of [Ru(bpy)2(pypmR)]2+ and [Ru(bpy)2((EtO)2pypmR)]2+. Emission spectra maxima are observed from 606 to 653 nm with the high energy absorptions associated with the pypm derivs. and the low energy absorptions associated with the pypn derivs. The oxidation potentials for Ru3+/2+ couples vary from +1.33 to +0.95 V vs. SSCE; ClpypnR ligands make Ru2+ more easily oxidizable. Redns. are ligand-centered and sequential for each ligand π* system; the order of decreasing ease of reduction in the complexes is pypmR.apprx.(EtO)2ClpypnPh. Excited-state Ru2+*/+ couples range from +0.77 to +0.46 V; those of Ru3+/2+* range from -0.56 to -0.96 V A variable-temperature emission lifetime study reveals a low-lying 3dd state with an energy gap between the 3MLCT and the 3dd (ΔE) ranging from 1800-3920 cm-1, the thermal deactivation rate consts. from 3dd (k1) vary from 1.4 + 1010 to 5 + 1014 s-1. The ground state pKa values of the complexes determined by spectrometric titration range from -4.1 to -6.7. The excited state pKa *(app) values measured by fluorescence titration range from 0.5 to 3.03.
IT 10198-78-4, 4,6-Dichloro-5-phenyl-2-(2-pyridyl)pyrimidine
RL: RCT (Reactant); RACT (Reactant or reagent)
(for preparation of ruthenium(II) pyridylpyrimidinone derivative complexes)
RN 10198-78-4 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-phenyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:394334 CAPLUS
DN 129:67791
TI Preparation of 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidines and related compounds as drugs
IN Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
PA Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
SO PCT Int. Appl., 232 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824782	A2	19980611	WO 1997-US22390	19971204
	WO 9824782	A3	19980827		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9710727	A	19980612	ZA 1997-10727	19971128
	CA 2274063	A1	19980611	CA 1997-2274063	19971204
	AU 9860120	A	19980629	AU 1998-60120	19971204
	AU 733877	B2	20010531		
	EP 948497	A2	19991013	EP 1997-954778	19971204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9713850	A	20000229	BR 1997-13850	19971204
	CN 1246858	A	20000308	CN 1997-181563	19971204
	HU 200001698	A2	20010428	HU 2000-1698	19971204
	HU 200001698	A3	20020729		
	NZ 335997	A	20010831	NZ 1997-335997	19971204
	JP 2002514195	T	20020514	JP 1998-525850	19971204
	TW 520362	B	20030211	TW 1997-86118244	19971204
	EP 1314731	A2	20030528	EP 2002-27704	19971204
	EP 1314731	A3	20040102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, AL				
	EP 1314732	A2	20030528	EP 2002-27705	19971204
	EP 1314732	A3	20040102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
	CZ 296911	B6	20060712	CZ 1999-2015	19971204
	ZA 9710911	A	19980605	ZA 1997-10911	19971205
	MX 9905168	A	20000228	MX 1999-5168	19990603
	US 6410729	B1	20020625	US 2000-598740	20000621
	US 2003069425	A1	20030410	US 2002-117552	20020403
	US 6610698	B2	20030826		
PRAI	US 1996-32128P	P	19961205		
	US 1997-50950P	P	19970613		
	US 1997-976054	A	19971121		
	EP 1997-954778	A3	19971204		
	US 1997-984774	B1	19971204		
	WO 1997-US22390	W	19971204		
	US 2000-598740	A3	20000621		

OS MARPAT 129:67791

AB Novel pyrimidines [I; R1, R2 = ZY, with a proviso; Z = bond, (un)substituted alk(en)yl, alkynyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl; etc; Y = H, halo, NO2, COR20, CNR5NR5R21, OR21, O2CR21, etc.; R5 = H, (un)substituted alk(en)yl, alkynyl, cycloalkyl, (hetero)aryl, etc.; R20 = (un)substituted alk(en)yl, alkynyl, aralkoxy, aralkylthio, aralkylsulfonyl, etc.; R21 = H, any of definitions for R20] and their pharmaceutically acceptable salts, effective for prophylaxis and treatment of diseases mediated by tumor necrosis factor α (TNF-α), IL-1β, IL-6 and/or IL-8 and other maladies, e.g., pain and diabetes, were prepared, e.g., by enamination of 2-(4-fluorophenyl)-1-(4-pyridinyl)ethanone (II) with (Me2N)2CHOMe and cyclocondensation of the resulting (dimethylamino)propenone with an amidine, guanidine or urea. I analogs, prodrugs , pharmaceutical compns., methods for prophylaxis and treatment of diseases or conditions involving inflammation, pain, diabetes, etc., and processes for making such compds. and their intermediates are also claimed. For example, heating a mixture of II with (Me2N)2CHOMe at 110° for 1.5 h under Ar gave 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridyl)-3-propen-1-one which was cyclocondensed with 4-pyridylamidine (prepared in situ from pyridylamidine-HCl and Na) by refluxing in EtOH to give a title compound I (R1 = R12 = 4-pyridinyl, R2 = H, R11 = 4-FC6H4). The latter in mice inhibited lipopolysaccharide-induced TNF-α release with IC50 ≤20 μM.

IT 20091-23-0P 208653-63-8P 208653-66-1P
208936-15-6P 208936-16-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-substituted (fluorophenyl)(pyridyl)pyrimidines and related compds. as drugs)

RN 20091-23-0 CAPLUS

CN 4(1H)-Pyrimidinone, 5-phenyl-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 208653-63-8 CAPLUS

CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 208653-66-1 CAPLUS

CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2,6-di-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 208936-15-6 CAPLUS
CN 4-Pyrimidinamine, 5-(4-fluorophenyl)-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 208936-16-7 CAPLUS
CN Pyrimidine, 4-methoxy-5-phenyl-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



IT 208936-42-9P 208936-43-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-substituted (fluorophenyl)(pyridyl)pyrimidines and related compds. as drugs)
RN 208936-42-9 CAPLUS
CN Pyrimidine, 4-chloro-5-phenyl-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 208936-43-0 CAPLUS
CN Pyrimidine, 4-chloro-5-(4-fluorophenyl)-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



L12 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:394333 CAPLUS
DN 129:54384
TI Preparation of arylpyrimidinones and analogs as drugs
IN Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.; Zablocki, Jeff A.
PA Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.; Zablocki, Jeff A.
SO PCT Int. Appl., 298 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824780	A2	19980611	WO 1997-US22949	19971204
	WO 9824780	A3	19980730		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, SZ, BE, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9710727	A	19980612	ZA 1997-10727	19971128
	CA 2274093	A1	19980611	CA 1997-2274093	19971204
	CA 2274093	C	20061107		
	AU 9855254	A	19980629	AU 1998-55254	19971204
	AU 735901	B2	20010719		
	EP 948496	A2	19991013	EP 1997-951678	19971204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1246857	A	20000308	CN 1997-181558	19971204
	BR 9713863	A	20000314	BR 1997-13863	19971204
	HU 200001140	A2	20010428	HU 2000-1140	19971204
	HU 200001140	A3	20020528		
	NZ 335992	A	20010928	NZ 1997-335992	19971204
	JP 2002514196	T	20020514	JP 1998-525902	19971204
	TW 520362	B	20030211	TW 1997-86118244	19971204
	EP 1314731	A2	20030528	EP 2002-27704	19971204
	EP 1314731	A3	20040102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, AL				
	EP 1314732	A2	20030528	EP 2002-27705	19971204
	EP 1314732	A3	20040102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
	ZA 9710911	A	19980605	ZA 1997-10911	19971205
	MX 9905158	A	20000331	MX 1999-5158	19990603
	US 6410729	B1	20020625	US 2000-598740	20000621
	US 2003069425	A1	20030410	US 2002-117552	20020403
	US 6610698	B2	20030826		
PRAI	US 1996-32128P	P	19961205		
	US 1997-50950P	P	19970613		
	US 1997-976053	A	19971121		
	US 1997-976054	A	19971121		
	EP 1997-954778	A3	19971204		
	US 1997-984774	B1	19971204		
	WO 1997-US22949	W	19971204		

US 2000-598740 A3 20000621
OS MARPAT 129:54384
AB Title compds. [e.g., I; Z = N or CR2; R1,R2 = R or Z1R; R = H, halo, alkoxy(carbonyl), amino(carbonyl or sulfonyl), etc.; R3 = Z1R; R4,R5 = (un)substituted (hetero)aryl; X = O, S, (un)substituted imino; Z1 = alkylene, heterocyclylene, (hetero)arylene, etc.] were prepared as agents for reduction of, e.g., TNF-α levels. Thus, 4-FC6H4CH2CO2Et was acylated by Et isonicotinate and the product cyclocondensed with (H2N)2CS to give, after N-methylation, I (R3 = Me, R4 = C6H4F-4, R5 = 4-pyridyl, X = O)(II; R1 = SH) which was aminated by 2-FC6H4CH(NH2)CH2CH2NH2 to give II [R1 = NHCH2CH2CH(NH2)C6H4F-2]. Data for biol. activity of I were given.
IT 20091-23-0P 208653-63-8P 208653-66-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrimidinones and analogs as drugs)
RN 20091-23-0 CAPLUS
CN 4(1H)-Pyrimidinone, 5-phenyl-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 208653-63-8 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 208653-66-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2,6-di-3-pyridinyl- (9CI) (CA INDEX NAME)


F
N
NH
O
N
N

L12 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:890091 CAPLUS
DN 123:286072
TI Preparation of (N-pyrimidinyl)benzenesulfonamide endothelin antagonists
IN Yamada, Koichiro; Yasuda, Kosuke; Kikkawa, Kohei; Kohno, Rikako Touwacity Co-op
PA Tanabe Seiyaku Co., Ltd., Japan
SO Eur. Pat. Appl., 74 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 658548	A1	19950621	EP 1994-119833	19941215
	EP 658548	B1	19971119		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	IL 111959	A	20000716	IL 1994-111959	19941212
	CA 2137953	A1	19950618	CA 1994-2137953	19941213
	CA 2137953	C	20020326		
	AU 9480461	A	19950622	AU 1994-80461	19941214
	AU 676620	B2	19970313		
	FI 9405900	A	19950618	FI 1994-5900	19941215
	FI 115137	B1	20050315		
	AT 160341	T	19971215	AT 1994-119833	19941215
	ES 2111237	T3	19980301	ES 1994-119833	19941215
	TW 430661	B	20010421	TW 1994-83111723	19941215
	JP 08099961	A	19960416	JP 1994-312280	19941216
	JP 2790065	B2	19980827		
	US 5589478	A	19961231	US 1994-356958	19941216
	CN 1111242	A	19951108	CN 1994-119413	19941217
	CN 1051544	B	20000419		
	US 5728706	A	19980317	US 1996-636981	19960424
PRAI	JP 1993-318779	A	19931217		
	JP 1994-140628	A	19940623		
	JP 1994-183553	A	19940804		
	US 1994-356958	A1	19941216		

OS MARPAT 123:286072
AB The title compds. [I; rings A and B are (un)substituted; A1 = lower alkylene, lower alkenylene; Q = single bond, O, S, SO, SO2, CH2; R = (un)substituted aromatic heterocyclic, (un)substituted aryl; R1 = H, trifluoromethyl, (un)substituted alkyl, (un)substituted alkenyl, mono- or dialkylamino, (un)substituted alkylthio group, (un)substituted alkoxy, (un)substituted alkynyl, etc.; Y = O, S, NH; Z = single bond, O, NH] (e.g., II; m.p. 128-129.5°), having endothelin antagonist activity (no data), useful in the prophylaxis or treatment of various diseases caused by endothelin (no data), are prepared
IT 848088-55-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (N-pyrimidinyl)benzenesulfonamide endothelin antagonists)
RN 848088-55-1 CAPLUS
CN Benzenesulfonamide, N-[6-chloro-5-(4-methylphenyl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


N
N
N
Cl
NH
S
O
O
Bu-t
Me

L12 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1991:429367 CAPLUS
DN 115:29367
TI Fungicidal pyridinylpyrimidinamines and their preparation
IN Giencke, Wolfgang; Sachse, Burkhard; Wicke, Heinrich
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 89 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 407899	A2	19910116	EP 1990-112903	19900706
	EP 407899	A3	19910724		
	EP 407899	B1	19950301		
	R: AT, CH, DE, ES, FR, GB, GR, IT, LI				
	DE 3922735	A1	19910124	DE 1989-3922735	19890711
	US 5250530	A	19931005	US 1990-549764	19900709
	HU 54280	A2	19910228	HU 1990-4151	19900710
PRAI	DE 1989-3922735	A	19890711		

OS MARPAT 115:29367
AB Title compds. I [R1 = H, alkyl, alkoxyalkyl, phenylalkyl, etc.; R2, R3, R4 = H, alkyl, (un)substituted phenyl; R5 = H, alkyl, cycloalkyl, alkoxy, alkylthio, etc.; R6 = H, alkyl, alkoxy, alkenyloxy, halo, (un)substituted Ph, etc.; R7, R8 = H, alkyl, alkoxyalkyl, phenylalkyl, etc.] were prepared as agricultural fungicides. Thus, 4-chloro-6-methyl-2-(2-methyl-6-pyridinyl)pyrimidine, PrNH2, K2CO3, and PhCH2N+Et3 Cl- were refluxed 7 h in MeCN to give 95% I (R1 = R5 = Me, R2 = R3 = R4 = R6 = R7 = H, R8 = Pr). When applied to barley plants at 500 mg/L of spray, several I showed 100% activity against organisms such as Erysiphe graminis.
IT 134545-17-8P 134545-18-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as fungicide)
RN 134545-17-8 CAPLUS
CN 4-Pyrimidinamine, N,N-diethyl-5-phenyl-2-(6-propyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 134545-18-9 CAPLUS
CN 4-Pyrimidinamine, N-ethyl-5-phenyl-2-(6-propyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


N
N
N
Pr-n
Ph
NHEt

L12 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1980:58722 CAPLUS
DN 92:58722
TI Reaction of amidoximes with diphenylcyclopropenone. Synthesis of 2-aryl-5,6-diphenylpyrimidin-4-ones
AU Takahashi, Masahiko; Watanabe, Shinichi
CS Fac. Eng., Ibaraki Univ., Hitachi, 316, Japan
SO Chemistry Letters (1979), (10), 1213-14
CODEN: CMLTAG; ISSN: 0366-7022
DT Journal
LA English
OS CASREACT 92:58722
AB Pyrimidinones I (R = Ph, 4-MeOC6H4, 4-MeC6H4, 4-BrC6H4, 4-ClC6H4, 3-O2NC6H4, 2-pyridyl) were prepared in 51-82% yields by cyclizing R(H2N)C:NOH with II in refluxing toluene 2 h.
IT 72455-80-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and spectral properties of)
RN 72455-80-2 CAPLUS
CN 4(1H)-Pyrimidinone, 5,6-diphenyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1971:141676 CAPLUS
DN 74:141676
TI Pyrimidine derivatives
AU Dymek, Wojciech; Zimon, Romuald
CS Akad. Med., Cracow, Pol.
SO Acta Poloniae Pharmaceutica (1970), 27(3), 199-204
CODEN: APPHAX; ISSN: 0001-6837
DT Journal
LA Polish
AB EtONa, R1R2C(CO2Et)2, and RC(:NH)NH2.HCl gave the following I (R = 2-pyridyl) (R1 and R2 given): H, H; H, Ph; H, Cl; Et, Et; H, NHAc. Also prepared were the following I (R = 3-pyridyl) (R1 and R2 given): H, H; H, Ph; H, Cl; Et, Et; H, NHAc. Similarly prepared was I (R = PhCH2, R1 = H, R2 = NHAc), which was hydrolyzed with concentrated HCl to I (R = PhCH2, R1 = H, R2 = NH2) (II). II refluxed with an aldehyde in EtOH gave III (R = PhCH:CHCH, o-HOC6H4CH, and o-ClC6H4CH. With PhSO3H II gave the N-(phenylsulfonyl) derivative
IT 31774-69-3P 31774-73-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31774-69-3 CAPLUS
CN 4,6(1H,5H)-Pyrimidinedione, 5-phenyl-2-(2-pyridyl)- (8CI) (CA INDEX NAME)



Claim 27 Requires Esub.

RN 31774-73-9 CAPLUS
CN 4,6(1H,5H)-Pyrimidinedione, 5-phenyl-2-(3-pyridyl)- (8CI) (CA INDEX NAME)



L12 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1968:487008 CAPLUS
DN 69:87008
TI 4-Hydroxypyrimidines
IN Kabbe, Hans J.; Eiter, Karl
PA Farbenfabriken Bayer A.-G.
SO Ger., 4 pp.
CODEN: GWXXAW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1271116		19680627	DE 1965-1271116	19650504

AB The title compds. (I) are obtained by the reaction of R1CH2CO2R2 with R3CN. At least an equimolar amount (based on R1CH2CO2R2) of an alkali alcoholate, alkali amide, or a high boiling tertiary amine is added to the reaction mixture and the temperature raised to 60-160°. Thus, 33 weight parts PhCH2CO2Et 42 parts α-cyanopyridine, and 12 parts MeONa was heated 20 min. at 110° and worked up to give 62% 2,6-di(α-pyridyl)-4-hydroxy-5-phenylpyrimidine, m. 227-8.5° (aqueous HOAc). Similarly prepared were the following I (R1, R2, and m.p. given): Ph, β-pyridyl, 308-13°; 2,5-dihydroxyphenyl, γ-pyridyl, 320° (decomposition); 2-chlorophenyl, α-pyridyl, >300°; 2-chlorophenyl, β-pyridyl, 232-8°; 2-chlorophenyl, γ-pyridyl, 290-5°; 4-chlorophenyl, α-pyridyl, 219-22°; 4-chlorophenyl, β-pyridyl, 280-5°; 4-chlorophenyl, γ-pyridyl, >330°; 3-chloro-4-methoxyphenyl, α-pyridyl, 250-2°; 3,4-dichlorophenyl, α-pyridyl, 212-13°; 3,4-dichlorophenyl, β-pyridyl, 282-6°; 3,4-dichlorophenyl, γ-pyridyl, 300-3°; 3,4-dichlorophenyl, 2-furyl, 263-6°; 2,4-dichlorophenyl, α-pyridyl, 320°; naphthyl, α-pyridyl, 248-52°; α-pyridyl, α-pyridyl, 218-21°; 3-indolyl, α-pyridyl, 266-7°; 2-furyl, α-pyridyl, 196-9°; and 1,2,3-triazolyl, α-pyridyl, 230° (decomposition). The new compds. have bacteriostatic properties.

IT 14756-87-7P 14756-88-8P 14756-89-9P
14756-90-2P 14756-91-3P 14756-92-4P
14756-93-5P 14756-94-6P 14756-95-7P
14756-96-8P 14756-97-9P 14756-98-0P
14757-00-7P 20091-23-0P 20091-25-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 14756-87-7 CAPLUS
CN 4-Pyrimidinol, 5-(o-chlorophenyl)-2,6-di-4-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-88-8 CAPLUS
CN 4-Pyrimidinol, 5-phenyl-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-89-9 CAPLUS
CN 4-Pyrimidinol, 5-phenyl-2,6-di-3-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-90-2 CAPLUS
CN 4-Pyrimidinol, 5-(o-chlorophenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



← Req. 2 Subs.

RN 14756-91-3 CAPLUS
CN 4-Pyrimidinol, 5-(o-chlorophenyl)-2,6-di-3-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-92-4 CAPLUS
CN 4-Pyrimidinol, 5-(p-chlorophenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-93-5 CAPLUS
CN 4-Pyrimidinol, 5-(p-chlorophenyl)-2,6-di-3-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-94-6 CAPLUS
CN 4-Pyrimidinol, 5-(p-chlorophenyl)-2,6-di-4-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-95-7 CAPLUS
CN 4-Pyrimidinol, 5-(3-chloro-4-methoxyphenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-96-8 CAPLUS
CN 4-Pyrimidinol, 5-(3,4-dichlorophenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-97-9 CAPLUS
CN 4-Pyrimidinol, 5-(3,4-dichlorophenyl)-2,6-di-3-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-98-0 CAPLUS
CN 4-Pyrimidinol, 5-(3,4-dichlorophenyl)-2,6-di-4-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-00-7 CAPLUS
CN 4-Pyrimidinol, 5-(2,4-dichlorophenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 20091-23-0 CAPLUS
CN 4(1H)-Pyrimidinone, 5-phenyl-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 20091-25-2 CAPLUS
CN Hydroquinone, (4-hydroxy-2,6-di-4-pyridyl-5-pyrimidinyl)- (8CI) (CA INDEX NAME)



L12 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1967:443794 CAPLUS
DN 67:43794
TI Heterocycles from carboxylic acid derivatives. II. Substituted 4-hydroxy- and 4-aminopyrimidines
AU Kabbe, Hans J.
CS Farbenfabriken Bayer A.-G., Leverkusen, Fed. Rep. Ger.
SO Justus Liebigs Annalen der Chemie (1967), 704, 144-9
CODEN: JLACBF; ISSN: 0075-4617
DT Journal
LA German
OS CASREACT 67:43794
AB cf. preceding abstract Acetic acid alkyl ester and arylacetic acid alkyl esters, R'CH2CO2R" (R' = H, Ph, substituted phenyl, 1-triazolyl, and 3-indolyl), react with nitriles RCN (R = 2-, 3-, and 4-pyridyl, and 2-furyl) (mole ratio 1:2) in the presence of NaOMe to give the corresponding 4-hydroxypyrimidines (I). Similarly, acetonitrile and arylacetonitriles, R'CH2CN (R' = H, Ph, substituted phenyl, 2-furyl, and 1-naphthyl methyl) react with nitriles, RCN (R = 2-, 3-, and 4-pyridyl, 2-furyl, and Ph), to give the corresponding 4-aminopyrimidines (II).
IT 14756-87-7P 14756-88-8P 14756-89-9P
14756-90-2P 14756-91-3P 14756-92-4P
14756-93-5P 14756-94-6P 14756-95-7P
14756-96-8P 14756-97-9P 14756-98-0P
14757-00-7P 14757-06-3P 14757-07-4P
14757-08-5P 14757-09-6P 14757-10-9P
14757-11-0P 14757-12-1P 14757-13-2P
14757-14-3P 14757-15-4P 14757-16-5P
14757-21-2P 14827-87-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 14756-87-7 CAPLUS
CN 4-Pyrimidinol, 5-(o-chlorophenyl)-2,6-di-4-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-88-8 CAPLUS
CN 4-Pyrimidinol, 5-phenyl-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-89-9 CAPLUS

CN 4-Pyrimidinol, 5-phenyl-2,6-di-3-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-90-2 CAPLUS
CN 4-Pyrimidinol, 5-(o-chlorophenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-91-3 CAPLUS
CN 4-Pyrimidinol, 5-(o-chlorophenyl)-2,6-di-3-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-92-4 CAPLUS
CN 4-Pyrimidinol, 5-(p-chlorophenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-93-5 CAPLUS
CN 4-Pyrimidinol, 5-(p-chlorophenyl)-2,6-di-3-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-94-6 CAPLUS
CN 4-Pyrimidinol, 5-(p-chlorophenyl)-2,6-di-4-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-95-7 CAPLUS
CN 4-Pyrimidinol, 5-(3-chloro-4-methoxyphenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-96-8 CAPLUS
CN 4-Pyrimidinol, 5-(3,4-dichlorophenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14756-97-9 CAPLUS
CN 4-Pyrimidinol, 5-(3,4-dichlorophenyl)-2,6-di-3-pyridyl- (8CI) (CA INDEX

NAME)



RN 14756-98-0 CAPLUS
CN 4-Pyrimidinol, 5-(3,4-dichlorophenyl)-2,6-di-4-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-00-7 CAPLUS
CN 4-Pyrimidinol, 5-(2,4-dichlorophenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-06-3 CAPLUS
CN 4-Pyrimidinamine, 5-(4-chlorophenyl)-2,6-di-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 14757-07-4 CAPLUS
CN Pyrimidine, 4-amino-5-phenyl-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-08-5 CAPLUS
CN Pyrimidine, 4-amino-5-phenyl-2,6-di-3-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-09-6 CAPLUS
CN Pyrimidine, 4-amino-2,6-di-2-pyridyl-5-p-tolyl- (8CI) (CA INDEX NAME)



RN 14757-10-9 CAPLUS
CN Pyrimidine, 4-amino-2,6-di-4-pyridyl-5-p-tolyl- (8CI) (CA INDEX NAME)



RN 14757-11-0 CAPLUS
CN Pyrimidine, 4-amino-5-(p-methoxyphenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-12-1 CAPLUS
CN Pyrimidine, 4-amino-5-(p-methoxyphenyl)-2,6-di-4-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-13-2 CAPLUS
CN Pyrimidine, 4-amino-5-(o-chlorophenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-14-3 CAPLUS
CN Pyrimidine, 4-amino-5-(o-chlorophenyl)-2,6-di-4-pyridyl- (8CI) (CA INDEX

NAME)



RN 14757-15-4 CAPLUS
CN Pyrimidine, 4-amino-5-(3-chloro-4-methoxyphenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-16-5 CAPLUS
CN Pyrimidine, 4-amino-5-(3,4-dichlorophenyl)-2,6-di-4-pyridyl- (8CI) (CA INDEX NAME)



RN 14757-21-2 CAPLUS
CN Pyrimidine, 4-amino-5-(3,4-dimethoxyphenyl)-2,6-di-2-pyridyl- (8CI) (CA INDEX NAME)



RN 14827-87-3 CAPLUS
CN 4-Pyrimidinol, 5-phenyl-2,6-di-4-pyridyl-, monoacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 20091-23-0
CMF C20 H14 N4 O



CM 2

CRN 64-19-7
CMF C2 H4 O2



L12 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1967:403054 CAPLUS
DN 67:3054
TI The preparation and properties of certain pyridylpyrimidines and bidiazines as potential chelating agents for iron(II)
AU Lafferty, John J.; Case, Francis H.
CS Temple Univ., Philadelphia, PA, USA
SO Journal of Organic Chemistry (1967), 32(5), 1591-6
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
AB A series of pyridylpyrimidines (I) and bidiazines related to the bidentate ligand 2,2 -bipyridine and the tridentate ligand 2,2',-2"-terpyridine were prepared and their ability to form stable chelates with Fe(II) in aqueous alc. solution investigated. In general the εmaximum values (visible) of the resp. chelates were less than those of the corresponding polypyridines.
IT 10198-76-2P 10198-78-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 10198-76-2 CAPLUS
CN 4,6-Pyrimidinediol, 5-phenyl-2-(2-pyridyl)- (8CI) (CA INDEX NAME)



Claim 27 requires 2 Subs.

RN 10198-78-4 CAPLUS
CN Pyrimidine, 4,6-dichloro-5-phenyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



```
=> => d his

     (FILE 'HOME' ENTERED AT 23:51:16 ON 29 MAR 2007)

     FILE 'REGISTRY' ENTERED AT 23:51:27 ON 29 MAR 2007
L1             STRUCTURE UPLOADED
L2           1 S L1 SSS SAM
L3             STRUCTURE UPLOADED
L4           4 S L3 SSS SAM
L5             STRUCTURE UPLOADED
L6           5 S L5 SSS SAM
L7         252 S L5 SSS FUL
L8             STRUCTURE UPLOADED
L9           3 S L8 SSS SAM  SUB=L7
L10         35 S L8 SSS FUL  SUB=L7
L11        217 S L7 NOT L10

     FILE 'CAPLUS' ENTERED AT 00:06:04 ON 30 MAR 2007
L12         31 S L11

     FILE 'CAOLD' ENTERED AT 00:06:47 ON 30 MAR 2007

=> s l11
L13          0 L11

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.45     385.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00     -24.18

STN INTERNATIONAL LOGOFF AT 00:07:08 ON 30 MAR 2007
```